Merck Archives - Vista Partners LLC | HomeVista Partners LLC

GeoVax Brings Its Differentiated Biotech Platform to Center Stage at J.P. Morgan Healthcare Week – Jan. 12-15 – ( $GOVX $MRK $IBB $XBI #JPM2026 )

by Vista Partners LLC January 6, 2026 32Views 0Likes

GeoVax Labs (NASDAQ: GOVX) is heading into the 44th Annual J.P. Morgan Healthcare Conference week ("JPM2026") in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and…

Radiopharmaceutical Gold Rush: Why Wall Street Is Finally Paying Attention to Nuclear Medicine -( $BMY $NVS $TLX )

by Vista Partners LLC December 23, 2025 371Views 0Likes

Radiopharmaceuticals are quietly becoming the part of oncology that no longer sits in the hospital basement—capital, M&A desks, and regulators have all joined the tour. For investors, the space now looks less like a scientific hobby and more like a pipeline strategy…

Merck Mixes Up Its Pipeline With Cidara $9.2B Acquisition—GeoVax Keeps Driving Towards Value in the Vaccine Lane -( $MRK $CDTX $GOVX $IBB )

by Vista Partners LLC November 15, 2025 317Views 0Likes

Merck (MRK), ever the discerning giant of Big Pharma, has decided to join the prophylactic party by acquiring Cidara Therapeutics (CDTX) for a headline-grabbing $9.2 billion—a move that whispers both “strategic pipeline expansion” and “Keytruda’s patent clock is ticking, folks.” In a…

U.S. Based GeoVax Labs Seeks To Challenge Bavarian Nordic’s Vaccine Monopoly Amid $3 Billion Buyout – ( $GOVX $BVNKF $IBB $XBI )

by John F. Heerdink, Jr. September 22, 2025 220Views 0Likes

GeoVax Labs, Inc. (NASDAQ: GOVX), an American clinical-stage biotechnology company, is advancing its Modified Vaccinia Ankara (MVA) vaccine platform, positioning itself as a key domestic alternative to Europe's Bavarian Nordic in addressing critical global health threats such as Mpox and smallpox. This…

Reinventing Diabetes Care: Modular Medical’s Bold Bet on Simpler, Smarter Insulin Delivery – ( $MODD )

by John F. Heerdink, Jr. August 7, 2025 171Views 0Likes

Modular Medical (NASDAQ: MODD), a potential disruptor in diabetes care technology, is rapidly moving from visionary concept to tangible innovation as it propels its FDA cleared MODD1 insulin patch pump toward commercial launch. The company has recently validated its MODD1 cartridge manufacturing…

U.S.-Based GeoVax Emerges as Key Monopoly Challenger Amid $2.99B Bavarian Nordic Takeover – ($GOVX $IBB $XBI)

by John F. Heerdink, Jr. July 31, 2025 178Views 0Likes

Bavarian Nordic, a leading Danish vaccine manufacturer best known for its MVA-BN (Modified Vaccinia Ankara–Bavarian Nordic) smallpox and mpox vaccines, recently agreed to a $2.99 billion takeover by private equity firms Permira and Nordic Capital. Shareholders are being offered 233 Danish kroner…

Merck Sets Its Sights on Eyebiotech: Pharma Giant Eyes $1.3 Billion Move Into Vision Care

by John F. Heerdink, Jr. July 11, 2025 108Views 0Likes

Merck (MRK) is setting its sights on a new frontier—your eyes. The pharmaceutical heavyweight is on the verge of acquiring Eyebiotech, an ophthalmology biotech upstart, in a deal valued at a crisp $1.3 billion. If finalized, this move would mark Merck’s debut into the…

Serina Therapeutics: Optimizing Drug Delivery for the Future – ( $SER )

by John F. Heerdink, Jr. July 7, 2025 123Views 0Likes

Serina Therapeutics (NYSE: SER) is positioning itself at the forefront of a new era in drug development, as highlighted in a recent corporate video titled "Rethinking Drug Development: Faster, Smarter, Strategic and reinforced by a series of strategic moves and partnerships.…

Modular Medical (Nasdaq: MODD) Unveils Updated Investor Presentation, Emphasizing Disruptive Business Model and Near-Term Milestones

by John F. Heerdink, Jr. June 30, 2025 249Views 0Likes

Over the weekend, Modular Medical, Inc. (Nasdaq: MODD), a San Diego-based innovator in insulin delivery technology, quietly published an updated investor presentation , signaling a new phase in its campaign to transform diabetes care. The release comes on the heels of the…

GeoVax Applauds FDA’s Green Light for Keytruda: A New Chapter in Head and Neck Cancer—and a Wink at Gedeptin’s Future – ( $GOVX $MRK $XBI )

by John F. Heerdink, Jr. June 24, 2025 152Views 0Likes

In the ever-evolving world of oncology, every so often a regulatory decision comes along that feels less like a footnote and more like a new chapter. The U.S. Food and Drug Administration’s (FDA) recent approval of Merck’s (MRK) Keytruda® (pembrolizumab) for resectable,…

Merck

Your Guide To Staying Informed In The Markets